IGFBP2 has been reported as a potential biomarker, particularly for AD, and we found that IGFBP2 expression levels were higher in participants with dementia than in those with MCI or cognitively normal participants, and it had a moderately negative association with cognitive performance scores. This evidence concerns the gene IGFBP2 and dementia.